C-Path’s Avilés Discusses Importance of Data Standards in FDA Week Article
FDA is encouraging industry to use newly crafted therapeutic data standards — such as utilization of qualified biomarkers– in submissions and could start requiring companies to use the standardized data elements in the future,sources said following the release of the first set of standardized therapeutic data elements for Alzheimer’s disease that they said could make reviews and approvals faster and more efficient.
